Trade 10x Genomics, Inc. - TXG CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 51.97 |
Open* | 53.18 |
1-Year Change* | -28.68% |
Day's Range* | 53.18 - 56.09 |
52 wk Range | 23.81-83.34 |
Average Volume (10 days) | 754.85K |
Average Volume (3 months) | 21.21M |
Market Cap | 6.00B |
P/E Ratio | -100.00K |
Shares Outstanding | 115.36M |
Revenue | 516.41M |
EPS | -1.46 |
Dividend (Yield %) | N/A |
Beta | 1.74 |
Next Earnings Date | May 2, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 55.73 | 3.30 | 6.29% | 52.43 | 56.16 | 52.01 |
Mar 30, 2023 | 51.97 | 0.76 | 1.48% | 51.21 | 52.32 | 51.07 |
Mar 29, 2023 | 50.69 | 1.41 | 2.86% | 49.28 | 50.98 | 49.00 |
Mar 28, 2023 | 48.81 | -0.45 | -0.91% | 49.26 | 49.42 | 48.27 |
Mar 27, 2023 | 49.70 | -0.68 | -1.35% | 50.38 | 51.52 | 49.29 |
Mar 24, 2023 | 50.12 | 2.16 | 4.50% | 47.96 | 50.30 | 47.65 |
Mar 23, 2023 | 48.97 | 0.03 | 0.06% | 48.94 | 51.49 | 48.48 |
Mar 22, 2023 | 48.69 | -1.39 | -2.78% | 50.08 | 51.08 | 48.61 |
Mar 21, 2023 | 50.03 | 1.83 | 3.80% | 48.20 | 50.25 | 47.91 |
Mar 20, 2023 | 47.76 | 0.30 | 0.63% | 47.46 | 48.56 | 46.76 |
Mar 17, 2023 | 48.08 | -1.09 | -2.22% | 49.17 | 49.71 | 47.66 |
Mar 16, 2023 | 50.25 | 2.49 | 5.21% | 47.76 | 50.90 | 47.60 |
Mar 15, 2023 | 48.54 | 1.45 | 3.08% | 47.09 | 49.32 | 47.08 |
Mar 14, 2023 | 48.63 | 0.07 | 0.14% | 48.56 | 49.52 | 48.06 |
Mar 13, 2023 | 47.44 | 3.47 | 7.89% | 43.97 | 49.32 | 43.97 |
Mar 10, 2023 | 44.93 | -1.55 | -3.33% | 46.48 | 46.49 | 43.15 |
Mar 9, 2023 | 47.00 | -1.65 | -3.39% | 48.65 | 49.98 | 46.93 |
Mar 8, 2023 | 48.95 | 1.16 | 2.43% | 47.79 | 49.49 | 47.24 |
Mar 7, 2023 | 48.16 | 0.10 | 0.21% | 48.06 | 49.75 | 47.48 |
Mar 6, 2023 | 48.39 | -2.30 | -4.54% | 50.69 | 50.80 | 48.13 |
10x Genomics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Revenue | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Cost of Revenue, Total | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Gross Profit | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Total Operating Expense | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Selling/General/Admin. Expenses, Total | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Research & Development | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Operating Income | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Interest Income (Expense), Net Non-Operating | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Other, Net | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Net Income Before Taxes | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Net Income After Taxes | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Net Income Before Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Total Extraordinary Items | |||||
Net Income | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Income Available to Common Excl. Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Income Available to Common Incl. Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Diluted Net Income | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Diluted Weighted Average Shares | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
Diluted EPS Excluding Extraordinary Items | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
Diluted Normalized EPS | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Unusual Expense (Income) | 0 | 0 | 4.121 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Revenue | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Cost of Revenue, Total | 36.827 | 30.377 | 27.704 | 25.478 | 27.598 |
Gross Profit | 119.405 | 100.695 | 86.905 | 89.018 | 115.932 |
Total Operating Expense | 179.328 | 171.068 | 177.726 | 156.231 | 159.36 |
Selling/General/Admin. Expenses, Total | 78.887 | 73.401 | 79.337 | 66.675 | 69.877 |
Research & Development | 63.614 | 67.29 | 70.685 | 64.078 | 61.885 |
Unusual Expense (Income) | 0 | 0 | |||
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
Operating Income | -23.096 | -39.996 | -63.117 | -41.735 | -15.83 |
Interest Income (Expense), Net Non-Operating | 2.69 | 1.911 | 1.129 | 0.441 | -0.168 |
Other, Net | 3.995 | -1.95 | -1.843 | -0.4 | 0.005 |
Net Income Before Taxes | -16.411 | -40.035 | -63.831 | -41.694 | -15.993 |
Net Income After Taxes | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Net Income Before Extra. Items | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Net Income | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Income Available to Common Excl. Extra. Items | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Income Available to Common Incl. Extra. Items | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Diluted Net Income | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Diluted Weighted Average Shares | 114.767 | 114.112 | 113.575 | 112.966 | 111.913 |
Diluted EPS Excluding Extraordinary Items | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 747.591 | 774.366 | 480.84 | 106.236 | 68.107 |
Cash and Short Term Investments | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Cash & Equivalents | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Total Receivables, Net | 85.254 | 51.208 | 33.371 | 29.566 | 13.341 |
Accounts Receivable - Trade, Net | 85.254 | 51.208 | 33.371 | 28.088 | 13.341 |
Total Inventory | 59.966 | 29.959 | 15.27 | 8.57 | 4.838 |
Prepaid Expenses | 13.896 | 13.029 | 8.033 | 3.02 | 2.071 |
Total Assets | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Property/Plant/Equipment, Total - Net | 230.41 | 119.823 | 48.821 | 11.127 | 6.925 |
Property/Plant/Equipment, Total - Gross | 279.431 | 150.325 | 67.876 | 25.21 | 17.958 |
Accumulated Depreciation, Total | -49.021 | -30.502 | -19.055 | -14.083 | -11.033 |
Other Long Term Assets, Total | 10.917 | 12.798 | 76.262 | 6.947 | 0.577 |
Total Current Liabilities | 110.357 | 118.126 | 63.049 | 32.362 | 22.141 |
Accounts Payable | 17.351 | 4.709 | 13.028 | 8.792 | 5.443 |
Accrued Expenses | 75.821 | 92.326 | 30.035 | 12.118 | 8.959 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | 4.224 | |
Other Current Liabilities, Total | 17.185 | 21.091 | 10.104 | 7.265 | 3.515 |
Total Liabilities | 201.258 | 190.269 | 185.84 | 101.053 | 29.704 |
Total Long Term Debt | 0 | 0 | 19.837 | 25.489 | 6.335 |
Long Term Debt | 0 | 19.837 | 25.489 | 6.335 | |
Other Liabilities, Total | 90.901 | 72.143 | 102.954 | 43.202 | 1.228 |
Total Equity | 817.568 | 739.072 | 420.083 | 23.257 | 45.905 |
Redeemable Preferred Stock | 0 | 243.244 | 158.414 | ||
Common Stock | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 1680.86 | 1544.22 | 682.494 | 11.165 | 6.136 |
Retained Earnings (Accumulated Deficit) | -863.321 | -805.098 | -262.367 | -231.116 | -118.631 |
Other Equity, Total | 0.022 | -0.05 | -0.046 | -0.037 | -0.015 |
Total Liabilities & Shareholders’ Equity | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Total Common Shares Outstanding | 112.515 | 108.486 | 96.2416 | 93.8497 | 93.8497 |
Other Current Assets, Total | 1.028 | 16.567 | |||
Intangibles, Net | 25.397 | 22.354 | |||
Goodwill, Net | 4.511 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 697.335 | 747.591 | 744.104 | 757.174 | 745.716 |
Cash and Short Term Investments | 539.323 | 587.447 | 600.44 | 621.958 | 617.195 |
Cash & Equivalents | 312.487 | 587.447 | 600.44 | 621.958 | 617.195 |
Total Receivables, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Accounts Receivable - Trade, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Total Inventory | 63.697 | 59.966 | 51.141 | 44.087 | 38.507 |
Prepaid Expenses | 17.762 | 13.896 | 14.065 | 13.298 | 14.442 |
Other Current Assets, Total | 0.027 | 1.028 | 0.028 | 18.151 | 18.164 |
Total Assets | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Property/Plant/Equipment, Total - Net | 265.88 | 230.41 | 203.304 | 176.454 | 163.666 |
Property/Plant/Equipment, Total - Gross | 279.431 | 247.698 | 215.665 | 198.415 | |
Accumulated Depreciation, Total | -49.021 | -44.394 | -39.211 | -34.749 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 24.764 | 25.397 | 26.041 | 26.693 | 27.342 |
Other Long Term Assets, Total | 10.761 | 10.917 | 12.612 | 12.747 | 12.798 |
Total Current Liabilities | 94.446 | 110.357 | 100.375 | 113.126 | 120.549 |
Accounts Payable | 18.956 | 17.351 | 17.037 | 16.181 | 15.578 |
Accrued Expenses | 59.913 | 75.821 | 69.92 | 85.598 | 95.307 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.577 | 17.185 | 13.418 | 11.347 | 9.664 |
Total Liabilities | 196.566 | 201.258 | 190.351 | 192.993 | 201.573 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 102.12 | 90.901 | 89.976 | 79.867 | 81.024 |
Total Equity | 806.685 | 817.568 | 800.221 | 784.586 | 752.46 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1714.86 | 1680.86 | 1644.9 | 1612.23 | 1569.06 |
Retained Earnings (Accumulated Deficit) | -905.734 | -863.321 | -844.872 | -827.701 | -816.649 |
Other Equity, Total | -2.443 | 0.022 | 0.194 | 0.058 | 0.048 |
Total Liabilities & Shareholders’ Equity | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Total Common Shares Outstanding | 113.276 | 112.515 | 111.537 | 110.74 | 109.589 |
Short Term Investments | 226.836 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Cash From Operating Activities | -33.606 | -21.373 | -217.898 | 34.627 | -76.409 |
Cash From Operating Activities | 25.368 | 21.118 | 14.012 | 7.066 | 3.905 |
Non-Cash Items | 146.443 | 103.177 | 361.202 | 14.048 | 4.156 |
Cash Taxes Paid | 3.925 | 8.66 | 0.28 | -0.022 | -0.006 |
Cash Interest Paid | 0.841 | 1.222 | 1.67 | 2.25 | 1.824 |
Changes in Working Capital | -39.417 | -87.445 | -50.381 | 44.764 | 28.015 |
Cash From Investing Activities | -350.887 | -106.729 | -38.394 | -42.767 | -6.709 |
Capital Expenditures | -131.661 | -101.278 | -38.394 | -42.767 | -6.709 |
Cash From Financing Activities | 15.817 | 35.297 | 468.906 | 414.59 | 105.367 |
Financing Cash Flow Items | -5.409 | -5.028 | -5.848 | 0 | |
Issuance (Retirement) of Stock, Net | 21.226 | 40.325 | 506.01 | 414.59 | 86.628 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -31.256 | 0 | 18.739 |
Foreign Exchange Effects | -0.044 | 0.234 | -0.463 | -0.045 | -0.018 |
Net Change in Cash | -368.72 | -92.571 | 212.151 | 406.405 | 22.231 |
Other Investing Cash Flow Items, Total | -219.226 | -5.451 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -166 | -148.785 | -106.871 | -42.413 | -58.223 |
Cash From Operating Activities | -33.606 | -47.329 | -37.765 | -20.802 | -21.373 |
Cash From Operating Activities | 25.368 | 18.847 | 12.691 | 6.191 | 21.118 |
Non-Cash Items | 146.443 | 102.681 | 66.548 | 28.014 | 103.177 |
Cash Taxes Paid | 3.925 | 3.649 | 3.319 | 2.9 | 8.66 |
Cash Interest Paid | 0.841 | 0.841 | 0.841 | 0.841 | 1.222 |
Changes in Working Capital | -39.417 | -20.072 | -10.133 | -12.594 | -87.445 |
Cash From Investing Activities | -350.887 | -317.715 | -285.085 | -257.558 | -106.729 |
Capital Expenditures | -131.661 | -91.927 | -55.355 | -28.136 | -101.278 |
Other Investing Cash Flow Items, Total | -219.226 | -225.788 | -229.73 | -229.422 | -5.451 |
Cash From Financing Activities | 15.817 | 10.816 | 8.777 | 2.417 | 35.297 |
Financing Cash Flow Items | -5.409 | -5.409 | -5.409 | -5.409 | -5.028 |
Issuance (Retirement) of Stock, Net | 21.226 | 16.225 | 14.186 | 7.826 | 40.325 |
Issuance (Retirement) of Debt, Net | 0 | 0 | |||
Foreign Exchange Effects | -0.044 | -0.295 | -0.21 | -0.018 | 0.234 |
Net Change in Cash | -368.72 | -354.523 | -314.283 | -275.961 | -92.571 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 9.4813 | 9210082 | -415196 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.8556 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6523 | 8404774 | 145652 | 2022-12-31 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.3511 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.4437 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3422 | 4217954 | 207975 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3012 | 3206783 | -184394 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.2549 | 3161803 | -518131 | 2022-12-31 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.0939 | 3005427 | 0 | 2022-12-31 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.6231 | 2548100 | -57577 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2421 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1979 | 2135038 | -17833 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.018 | 1960300 | -337642 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.507 | 1463901 | 1108820 | 2022-12-31 | HIGH |
Brown Capital Management, LLC | Investment Advisor | 1.4964 | 1453630 | -161463 | 2022-12-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 1.3985 | 1358528 | -1145000 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3854 | 1345749 | -18168 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3601 | 1321234 | 63324 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.2491 | 1213394 | 999487 | 2022-12-31 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.2158 | 1180996 | 27291 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com